Almirall and Proteros Biostructures Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration
2008-07-24 08:05:00
Almirall and Proteros Biostructures Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration
BARCELONA, Spain–(EMWNews)–Laboratorios Almirall S.A. and Proteros biostructures GmbH announced
that they have achieved a scientific milestone in their collaboration –in
force since mid 2006- to solve structures of a prominent Almirall drug
discovery target in combination with proprietary Almirall compounds
triggering commercial payments to Proteros.
Proteros applied its industrial structural biology platform and
proprietary technologies to deliver protein ligand structures to
Almirall Scientists for a known, extremely challenging protein where
little published data is available, particularly on solving specific
protein ligand structures. Proteros delivered the solved structures
within the timeframes agreed at the beginning of the collaboration.
Almirall’s Executive Director for the R&D
Area, Dr Per Olof Andersson said: “the
relationship with Proteros is an excellent example of Almirall’s
strategy of accessing cutting edge science by collaborating with leading
external providers to compliment our internal resources and ultimately
accelerate our drug discovery programmes.”
Commenting on this achievement, Proteros Chief Executive Officer, Dr
Torsten Neuefeind said: “we are
pleased that Proteros’ approach to structural
biology, of applying our unique technologies in an industrial process,
has proven to offer an effective and valuable service to our client’s
scientists allowing them to make early decision on their drug discovery
programmes. We look forward to delivering similar valuable structural
information on our current and future collaborations with Almirall”.
Almirall
Almirall, an international pharmaceutical company based on innovation
and committed to health, headquartered in Barcelona, Spain, researches,
develops, manufactures and commercialises its own R&D and licensed drugs
with the aim of improving people’s health and
wellbeing. The therapeutic areas on which Almirall focuses its research
resources are related to the treatment of asthma, COPD (Chronic
Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis and
multiple sclerosis. Almirall’s medicines are
currently present in over 70 countries with direct presence in Europe
and Latin America in 11 countries.
For further information please visit the website at: www.almirall.com
Proteros Biostructures GmbH
Proteros biostructures provides services and unique technologies for
X-ray protein structure analysis and fragment screening to the life
science industries. The company accelerates and improves structure
analysis and structure-based drug discovery by its expertise,
industrialised process and unique technologies, e.g. Free Mounting SystemTM
and PicodropperTM, enabling cost-efficient
protein-ligand-structure analyses and compound kinetic profiling.
Proteros complements its clients’ internal
capabilities with its external expertise and access to flexible
resources. Proteros currently provides services to over fifty
pharmaceutical and biotechnology companies in North America, Europe and
Japan. More information about Proteros can be found on the company’s
website at www.proteros.com.
|
Almirall: 91 788 32 00 Neuefeind, Ph.D. 761-0 |
|
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89
Get Unlimited Organic Website Traffic to your Website
TheNFG.com now offers Organic Lead Generation & Traffic Solutions
